The objective of this study was to determine the association of 5-HT2C (serotonin 2C receptor) and MDR1 (multidrug resistant protein) genetic polymorphisms and antipsychotic-induced metabolic abnormalities among female patients with DSM IV schizophrenia spectrum disorders. We have previously reported the associations of À759CT 5-HT2C and G2677T and C3435T MDR1 genetic polymorphisms and olanzapine/risperidone-induced weight gain in a similar sample of patients. Here, we included a total of 101 previously non-medicated female patients treated with olanzapine/risperidone over a 3-month period. The variables analyzed included fasting glucose, total cholesterol, low-density lipoprotein, high-density lipoprotein and triglyceride levels in blood, blood pressure and waist circumferences. We observed significant association of À759T 5-HT2C genetic variant and greater increase in waist circumference (P ¼ 0.03), fasting glucose level (P ¼ 0.046) and triglyceride level (P ¼ 0.045) in blood after a 3-month period. The 2677T and 3435T MDR1 genetic variants were significantly associated with the greater increase in fasting glucose level in blood when patients were using olanzapine (Po0.001 and P ¼ 0.028, respectively). Our data indicate a possible influence of À759CT 5-HT2C and MDR1 G2677T and C3435T MDR1 genetic polymorphisms on the development of metabolic abnormalities among female patients treated with olanzapine/risperidone.
Introduction
Second-generation antipsychotics (SGAs) have brought progress in the treatment of patients with schizophrenia. In comparison with typical antipsychotics, their treatment efficacy spectrum is broader and side-effects spectrum is quite different. 1 Some SGAs have a greater potential of inducing glucose intolerance and hyperlipidemia, than typical antipsychotics, that might develop after just a few weeks of treatment with SGAs. [2] [3] [4] Metabolic syndrome, the term used to describe the co-occurrence abdominal obesity and several other abovementioned metabolic abnormalities, 5 occurs in about 50% of patients with schizophrenia, which is significantly higher when compared to the general population. 6 Since metabolic syndrome is associated with high morbidity and increased risk of incompliance to antipsychotic treatment, it tends to have a 'destructive' influence on patients' health and on treatment itself in a large number of patients.
However, clear inter-individual differences suggest that the individual predisposition, as a specific genetic make-up, may have a role in antipsychotic-induced metabolic abnormalities. Indeed, it was previously suggested that genetic variants of various target receptors could serve as potential gene markers in the prediction of weight gain, which is one of the major risk factors for other mentioned metabolic abnormalities. 7 We have previously reported the association study of 5-HT2C and MDR1 genetic polymorphisms and olanzapine/ risperidone-induced weight gain in a similar sample of patients, in which we found that MDR1 polymorphisms might influence risperidone-induced weight gain, and that the influence of 5-HT2C is of borderline significance. 8 Although weight gain usually correlates highly with some of the metabolic syndrome items, especially waist circumference, this is not always the case. 9 Abdominal obesity is the main characteristic of the metabolic syndrome and might also be the cause of it. 5 Furthermore, diabetes was observed in patients as a separate and possibly a schizophrenia-related factor even before the antipsychotic era. 10 Therefore, in addition to weight gain, the follow-up of other metabolic abnormalities provides additional data and a more comprehensive view on metabolic disturbances associated with the application of antipsychotics in patients with schizophrenia. The aim of this study was to investigate the potential influence of 5-HT2C (promoter region À759CT; rs3813929) and MDR1 polymorphisms (exon 26 C3435T; rs1045642 and exon 21 G2677T; rs2032582) on olanzapineand risperidone-induced metabolic abnormalities in female drug-naive patients with schizophrenia spectrum disorders.
The rationale for including 5-HT2C serotonin receptor and MDR1 genetic polymorphisms in the association study of antipsychotic-induced metabolic abnormalities is given below.
Serotonin receptor 5-HT2C
From studies involving animal subjects, it seems that 5-HT2C, on which both olanzapine and risperidone exhibit strong antagonistic effects, 1, 11 is one of the major gene candidate for the regulation of weight gain 12 and glycemia. 13 The role of its À759CT promoter polymorphism (rs3813929) in SGA-induced weight gain was extensively studied, [14] [15] [16] [17] [18] [19] [20] [21] although association studies of the same polymorphism and SGA-induced metabolic disturbances are very few, and with different conclusions. 22, 23 P-glycoprotein Although it is not known for other metabolic abnormalities, SGA-induced weight gain is thought to be dose independent. 24 However, apart from dose, plasma olanzapine and risperidone levels and their access to the brain might depend on the P-glycoprotein (P-gp), which has a major role in absorption, distribution and elimination of drugs. 25 It is widely localized in the luminal membranes of endothelial cells in cerebral capillaries forming the blood-brain barrier. 26 P-gp may, in various degrees, influence the access of antipsychotics to the brain. Olanzapine is ranked as an intermediate 27 and risperidone as a strong P-gp substrate.
28
P-glycoprotein is coded by MDR1 (or ABCB1) gene. 29 Two functional MDR1 single-nucleotide polymorphisms: silent mutation, C3435T, in exon 26 (rs1045642) and exon 21 single-nucleotide polymorphism, G2677T, (rs2032582) might influence the on expression of MDR1. 30 To the best of our knowledge, no association studies on MDR1 polymorphisms and metabolic abnormalities have been reported previously and only few studies have analyzed the association of weight gain and MDR1 polymorphisms, 8, 31 including the one conducted by our team.
Materials and methods

Subjects
We analyzed a cohort of 101 previously non-medicated, drug-naive, female patients, age ranging from 18 to 50 years (mean age±s.d. ¼ 33.47±10.62 years), Caucasian, and diagnosed with diagnostic and statistic manual of mental disorders (DSM IV) schizophrenia spectrum disorders as follows-schizophrenia (N ¼ 77), schizoaffective (N ¼ 7) and delusional disorder (N ¼ 17), acutely psychotic (mean positive and negative syndrome scale (PANSS) ± s.d. ¼ 95 ± 21). All relevant clinical data at baseline are given in Tables 1, 2  and 3 . With the exception of seven new patients, all patients were included in a previous study by our group as described in Medved et al. 32 The complete list of inclusion and exclusion criteria is given in the same publication. Similarly, all sociodemographic data do not differ significantly from those described in our previous publication. 32 All participants gave informed consent for participation in the study after receiving explanations and answers about the 1 , mean dose ± s.d. ¼ 3.50 ± 1.09). First clinical measurements were performed at the beginning of the treatment using SGA, during the first few days after admission in the hospital, and the second measurement on outpatients' visits after a 3-month period. Measurements were performed in mornings, after a 12-h fasting period and included: fasting glucose level in blood, total cholesterol, lowdensity lipoprotein, high-density lipoprotein and triglyceride levels (measured in the clinical lab and determined by a commercial enzyme assay test), blood pressure and waist circumferences. All blood samples were collected from the cubital vein. Waist measurements for four patients and triglyceride level for one patient at the beginning of the treatment with SGA could not be obtained.
At the beginning of the treatment and after 3 months of treatment, we determined the occurrence of metabolic syndrome, according to the International Diabetes Federation criteria. 
Genotyping
Genomic DNA was freshly isolated from leukocytes (EDTAanticoagulated blood) using the salting-out method. 33 Genotyping procedures for the analysis of À759CT allelic variants of 5-HT2C gene and analysis of 2677G/T/A polymorphisms in exon 21 and C3435T polymorphism have been described in our previous publication. 8 
Statistical analysis
A test for Hardy-Weinberg equilibrium using Markov chain method, 34 and linkage-disequilibrium (LD) likelihood ratio test between loci, gametic phase of which is unknown, 35 were performed, using the program Arlequin ver 3.01. 36 Repeated measures analysis of variance was used to assess the associations between the increases of each component of metabolic syndrome with genetic variants. In case of significant interaction, age or baseline body mass index was introduced as a covariate. First, individual genetic variants were used as a between-subject factor, and in the case of significance other factors were induced: positive family history of any the following: diabetes mellitus, cerebrovascular disorders and obesity; diagnosis, tobacco usage and duration of illness.
The associations of 5-HT2C and MDR1 genotypes and MDR1 haplotypes with the development of metabolic syndrome were studied using UNPHASED version 3.0.10 37 Furthermore, the associations of MDR1 haplotypes and percentages of changes of each component of metabolic syndrome were studied using UNPHASED version 3.0.10. 37 Age, duration of illness, diagnosis, family history of diabetes mellitus (DM), cerebrovascular disorders and obesity and tobacco usage were used as covariates.
In case of significant associations, further analyses were also performed among the group of patients treated with olanzapine and risperidone, separately. Among others, average dose of olanzapine or risperidone was included as a covariate.
All statistical analyses were carried out using SPSS 13.0 (SSPS, Chicago, IL, USA) statistical software package. The sequential Bonferroni adjustments 38, 39 were applied to correct for the effect of multiple tests using SAS release 8.02 (SAS Institute).
Results
Out of 101 patients included in the study, 17 have already developed the symptoms for metabolic syndrome before the beginning of the treatment with SGAs. Thus, 84 patients did not fulfill the criteria for the metabolic syndrome before the beginning of the SGAs treatment. After 3 months of SGAs treatment, 15 more, out of these 84 patients developed metabolic syndrome symptoms. All 17 patients who had developed the symptoms for metabolic syndrome before SGA treatment still fulfilled the criteria for the metabolic syndrome after 3 months of treatment.
The metabolic features of patients at baseline and after 3 months of risperidone or olanzapine treatment are shown in Tables 1, 2 and 3. Frequencies of CC, CT and TT of À759CT 5-HT2C were 55, 38 and 8, respectively; frequencies of GG, GT and TT exon 21 G2677T MDR1 were 40, 49 and 12, respectively; frequencies of CC, CT and TT of exon 26 C3435T MDR1 were 26, 45 and 30, respectively. As none of the patients in our sample had A allele variant of the exon 21 2677 G/T/A polymorphisms, we will refer to this polymorphic loci as exon 21 G2677T. No significant deviations from the expected Hardy-Weinberg proportions were observed in the sample (À759CT 5-HT2C: P ¼ 0.799; exon 21 G2677T, P ¼ 0.669and exon 26 C3435T, P ¼ 0.545). Test results for LD between loci exon 21 G2677T and exon 26 C3435T were found to be significant (w 2 ¼ 82.8759, Po0.0001, degree of freedom
Associations of metabolic abnormalities and 5-HT2C
The greatest increase in waist circumference was significantly associated with the absence of À759C allele of the 5-HT2C genotype (C vs no C: Figure 1 ). After correction for multiple testing, this association would be close to statistical significance, but no reaching it (a ¼ 0.025). Similarly, more increase in glucose blood levels between two measures was found to be significantly associated with the absence of À759C allele of the 5-HT2C genotype (C vs no C: F ¼ 4.067, d.f. ¼ 1, P ¼ 0.046), but it did not remain positive after Bonferroni adjustments (a ¼ 0.025; Figure 2 ). However, when olanzapine-and risperidone-treated patients were analyzed separately, the statistical significance was obtained only among olanzapine-treated patients (C vs no C: F ¼ 6.001, d.f. ¼ 1, P ¼ 0.017, mean ± s.d. baseline C vs no C 4.78 ± 0.475 vs 4.98 ± 1.19 increased to 5.11 ± 0.82 vs 6.7±4.47) and remained positive after Bonferroni adjustments (a ¼ 0.025).
The greatest change in the triglyceride blood level between two measures was significantly associated with À759CC 5-HT2C genotype (CC vs CT vs TT: P ¼ 0.045, . However, when olanzapine-and risperidone-treated patients were analyzed separately, the statistical significance was lost in both groups (data not shown). When smoking was introduced in the analysis as a between-subject factor, a significant association with the increase in the triglyceride blood level was observed in patients with the absence of À759C allele (mean ± s.d. baseline C vs no C: 1.65 ± 0.95 vs 1.83 ± 1.03 increased to 1.94 ± 1.22 vs 3.81±1.03; P ¼ 0.002, F ¼ 9.866, d.f. ¼ 1), which remained positive after Bonferroni adjustments.
Associations of metabolic abnormalities and MDR1
The increase in waist circumferences was not associated with MDR1 genotypes (G2677T:
However, the greatest increase in glucose blood levels between two measures was found to be significantly associated with T2677T MDR1 genotype (baseline mean ± s. In haplotype-based analysis, only the association of MDR1 haplotypes with the percentages of changes of glucose in blood was significant (log likelihood ratio test w 2 ¼ 8.528, d.f. ¼ 3, P-value ¼ 0.036). In specific test analysis, in which one single haplotype was compared against all the others, the greatest increase was positively associated with T-C haplotype (AddValue ¼ 0.0455, confidence interval ¼ À0.007 to À0.084, specific w 2 ¼ 5.944, d.f. ¼ 1, P ¼ 0.014), which, however, didn't remain statistically significant after Bonferroni correction (a ¼ 0.0125). 
The change of high-density lipoprotein blood levels between two measures was not associated with 5-HT2C
The increase in low-density lipoprotein blood levels between two measures was not associated with 5-HT2C
The increase in the triglyceride blood level between two measures was not associated with MDR1 genotypes (G2677T:
Associations of metabolic syndrome and 5-HT2C and MDR1 genetic polymorphisms No differences in allele and genotype and haplotype distributions of all studied genes were found when patients were divided in groups according to their development of metabolic syndrome (Table 4, Table 5 ). Additional analysis was carried out without the patients who had developed the symptoms for metabolic syndrome before SGA treatment (N ¼ 84), but again, no differences in allele and genotype and haplotype distributions were found (data not shown).
Discussion
The major findings of this study are: (1) significant associations of SGAs-induced glucose intolerance and triglyceride increase and À759T 5-HT2C variant and associations of SGAs-induced waist circumference increase and À759T 5-HT2C variant of borderline significance; (2) significant association of olanzapine-induced glucose intolerance and MDR1 G2677T polymorphism and borderline association of olanzapine-induced glucose intolerance and MDR1 C3435T polymorphism.
À759 5-HT2C genetic polymorphism
We found significant association of T variant of À759CT 5-HT2C polymorphism and olanzapine/risperidone-induced glucose intolerance and triglycerides in blood, and association of borderline significance of the same variant with the increased waist circumference among previously non-medicated patients with schizophrenia spectrum disorders. These findings are consistent with the hypothesis that abdominal obesity is the cause of metabolic syndrome leading to insulin resistance, hyperinsulinemia, glucose intolerance and finally to diabetes and dyslipidemia, rather than a component of it.
5 Consistent with that, carriers of À759C variants were at lower risk to develop abdominal obesity, glucose intolerance and perhaps hyperlipidemia in comparison with those without the À759C variant, especially when treated with an antipsychotic that has a diabetogenic profile, such as olanzapine. [2] [3] [4] In comparison with the results of our previous study, in which we did not obtain a significant association of 759CT 5-HT2C genetic polymorphisms and antipsychotic-induced weight gain among female schizophrenic patients, the obtained P-value was suggestive of the positive association of À759T variant and more weight gain (P ¼ 0.057). 8 Weight gain usually highly correlates with some of the metabolic syndrome items, but it is not always the case. 9 Furthermore, the increase in the number of drug-naive patients in this study might have conferred the stronger statistical associations that we observed here.
As per our knowledge, there are only few studies on the association of À759CT 5-HT2C polymorphism and SGAinduced metabolic abnormalities. Previously, Yevtushenko et al. 22 reported the association of C variant of the same polymorphism and increased waist circumference in male patients with schizophrenia after clozapine application. Mulder et al. 23 reported no association of À759CT genotype and metabolic syndrome development and waist circumference changes in a cross-sectional study on a sample of patients with chronic schizophrenia. However, the associations of À759CT 5-HT2C polymorphism and SGA-induced weight gain were extensively studied. Although recent studies found less weight gain in subjects bearing the T allele, [17] [18] [19] [20] previous studies reported opposite results 14 or found no associations. [14] [15] [16] 20 In the meta analysis by De Luca et al., 21 which included the majority of aforementioned studies published by 2005, higher weight gain associated with the C variant was reported, although significant heterogeneity among published studies has been noted.
Our study results seem discordant from the majority of abovementioned new association studies, including weight gain and metabolic syndrome development and À759CT 5-HT2C polymorphism. However, it is also possible that our results might, in fact, confirm the associations of À759CT 5-HT2C polymorphism and metabolic syndrome found by Yevtushenko et al., 22 and other studies that found positive association of À759CT variant and weight gain, [17] [18] [19] [20] [21] regardless of the opposite direction of the association that we observed. Interestingly, as in the case of weight gain, an increasing number of publications are replicating a previously reported pharmacogenetic-marker association, but with the risk allele reversed from the previous report. Although one way to explain these discrepancies might be to look for differences among studies (for example, sample differences in sex, drug-naive vs chronic patients, different medication or differences in duration of studies; 19 another possible explanation is that these opposite associations may indeed be confirmations that an active variant significantly affects a studied phenomena. Lin et al. 40 argued that multilocus effects and variation in interlocus correlations contribute to this so-called flip-flop phenomenon. Using theoretical modeling they demonstrated that flip-flop associations can occur when the investigated variant is correlated, through interactive effects or LD, particularly when the risk allele at the target locus is a relatively common allele, and when LD between loci varies across populations or within a population (especially with markers with low LD with each other). 40 Interestingly, McCarthy et al. 41 showed that LD pattern between the À759CT polymorphic locus and intragenic polymorphisms is disturbed and variable because of the genetic recombination and conversion, which could mean that the obtained associations of À759CT with a phenomenon that it is in a causal relationship with can be subjected to flip-flop variations.
Furthermore, although there are reports that À759T variant is associated with increased transcription of the 5-HT2C gene, 42, 43 studies show that 5-HT2C transcription activity might depend on other factors: sex, as investigations with Macaque rhesus monkeys revealed significant influence of estrogen and progesterone on 5-HT2C expression in ventromedial, dorsal and posterior hypothalamic regions; 44 
MDR1 genetic polymorphisms
To the best of our knowledge, this is the first report of an association of olanzapine-induced glucose intolerance and MDR1 G2677T polymorphism or MDR1 C3435T polymorphism among previously non-medicated patients with schizophrenia spectrum disorders. Although no association studies on MDR1 polymorphisms and metabolic abnormalities were reported, there were few studies that analyzed associations of weight gain and MDR1 polymorphisms, 8, 31 including the one conducted by our team. Although Lin et al. 40 found no associations of olanzapine-induced weight gain and MDR1 variants, 31 we found positive associations of risperidon, but not olanzapine-induced weight gain, and both MDR1 variants. 8 There are few possible explanations for the seemingly discordant results of this study with the previous studies. Insulin levels increase after antipsychotic treatment due to the development of peripheral resistance to insulin, and do not always correlate with weight gain. 48 Furthermore, although diabetes was observed in patients as a separate, and possibly schizophrenia-related factor, even before the antipsychotic era, 10 it might be possible that olanzapine application can enhance the predisposed reaction, especially considering its superb diabetogenic potential, [2] [3] [4] 32 which might provide an explanation for the stronger associations of glucose intolerance and studied MDR1 variants among olanzapine-treated patients.
Furthermore, the lesser number of risperidone-treated patients could explain why the associations of MDR1 variants and metabolic disturbances were not observed, despite the fact that risperidone is a stronger MDR1 substrate, when compared with olanzapine.
According to our results, we assume that 2677T variant was associated with lower P-gp function and higher SGA accessibility to the brain, and also higher concentrations in the tissue. Higher SGA concentrations in the brain of 2677T carriers compared with G2677 carriers would allow stronger effects of SGAs, including their effects on metabolic effects, that is, by modulating receptors involved in appetite increase. However, other mechanisms might be involved. After an oral application of SGAs, these medications mostly accumulate in peripheral tissues (digestive), 49 whereas only a small portion circulates in blood. Given the widespread distribution of P-gp protein and its function in olanzapine and risperidone tissue distribution, it is logical to assume that carriers of T variants, with lower functioning P-gp, have higher peripheral drug concentrations. However, the question arises whether risperidone or olanzapine might act on periphery. Ader 50 showed that olanzapine might reduce the inhibitory effect of insulin on gluconeogenesis in the liver and might reduce compensator insulin hyper secretion in case of insulin resistance without inducing abdominal obesity in dogs. In humans, there have been several reports of acute pancreatitis in patients treated with olanzapine and risperidone, as well, which might also suggest a peripheral effect of both medications 51, 52 Although exon 26 C3435T genotype also seems to influence MDR1 expression per se, other explanations are possible. Considering that exon 26 C3435T is a silent mutation, 30 it might be possible that observed associations are due to its LD with exon 21 G2677T or other mutations. 30 There were several limitations in this study, which should be acknowledged. First, as olanzapine and risperidone blood concentrations were not measured in this study, we are able to present only indirect associations between the studied MDR1 polymorphisms and SGA-induced metabolic disturbances. Second, all measurements in the second time point were performed during outpatients' visits. During the period of outpatient treatment, we were unable to record patients' eating habits, type of diet or exercise habits, which might result in changes of their daily energy expenditure. Third, all study subjects were women, which puts a limitation to generalization of our findings, although it also contributes to the homogeneity of the study sample, as gender differences in the development of metabolic abnormalities have been described. 53 Fourth, the relatively small number of subjects in each group after their division into different SGAs groups might have contributed to the relatively modest statistical significances obtained, especially among risperidone-treated patients.
We, to the best of our knowledge, have for the first time found association of À759CT 5-HT2C and MDR1 G2677T and C3435T polymorphisms and SGA-induced metabolic disturbances among patients with schizophrenia spectrum disorders. As a strong point of this study, we emphasize that our patients were drug naive before the beginning of the study, limiting the influence of one of the most confounding factors in previous studies. Despite the fact that our results are promising, it will be critically important to validate these findings in larger cohorts of patients in a longer follow-up design to firmly establish the potential of these polymorphisms as pharmacogenetic markers of SGAinduced metabolic abnormalities.
